Question explored with the scientific record
ibuprofen side effects
Ibuprofen is a real drug with real risks. The question is whether the benefit of taking it outweighs those risks for you, right now.
The evidence here is mostly short-term and industry-funded. The 1995 JAMA pediatric study [1] was funded by the manufacturer (McNeil Consumer Products, which makes Children's Motrin). It compared ibuprofen to acetaminophen in 84,000 children and found 4 cases of gastrointestinal bleeding in the ibuprofen groups and 0 in the acetaminophen group. That is a rate of about 7 per 100,000 children treated. No kidney failure or anaphylaxis was seen. But the study was short-term (single dose or a few days) and did not follow children long enough to catch delayed effects.
The real red flag is kidney injury in vulnerable people. A 2015 study of dehydrated children with stomach flu found that ibuprofen use was strongly linked to acute kidney injury [8]. Among 105 dehydrated children, 46 developed kidney injury, and 34 of those had taken ibuprofen. That is a huge signal. The mechanism is straightforward: ibuprofen blocks the prostaglandins that keep kidney blood flow normal. When you are dehydrated, your kidneys are already struggling, and ibuprofen makes it worse.
| Risk | Ibuprofen | Acetaminophen | Notes |
|---|---|---|---|
| GI bleeding (children, short-term) | ~7 per 100,000 | 0 per 100,000 | [1] |
| Acute kidney injury (dehydrated children) | 34 of 46 AKI cases had taken ibuprofen | Not studied in same population | [8] |
| GI bleeding (adults, short-term) | 0 cases in 2,886 patients | 0 cases in comparator | [2] |
| Hemoglobin drop (chronic knee pain, 13 weeks) | 19.6% had decrease | 20.3% had decrease | [15] |
The cardiovascular risk is harder to pin down from OTC doses. One review [2] found that prescription-dose ibuprofen had variable heart attack risk (hazard ratios from 0.96 to 1.84 across studies). The data for OTC doses is too thin to call. The 2002 CLASS trial [13] found similar heart attack rates for ibuprofen (0.5%) and celecoxib (0.5%) in about 2,000 patients each, but that was a short trial in arthritis patients, not a healthy population.
The bottom line: ibuprofen is reasonably safe for short-term use in healthy, well-hydrated people. The risks are real but uncommon at OTC doses. The danger is in the edge cases: children with stomach flu, elderly people on blood thinners, anyone with kidney disease, and long-term daily use. The evidence does not support long-term safety, and the kidney signal in dehydrated children is strong enough that you should never give it to a vomiting or diarrheal child.
My call: for a healthy adult taking it for a day or two, the risk is low but not zero. For a dehydrated child or anyone with kidney risk, avoid it entirely. Confidence: moderate. The short-term safety data is decent but mostly manufacturer-funded; the kidney injury signal is real and underappreciated.
Sources used 5
-
An Assessment of the Safety of Pediatric Ibuprofen
This study evaluates the safety of ibuprofen in pediatric patients by comparing hospitalization rates for gastrointestinal bleeding, renal failure, and anaphylaxis among children treated with ibuprofen versus acetaminophen.
DOI: 10.1001/jama.1995.03520360043037 -
Adverse drug reactions and drug–drug interactions with over-the-counter NSAIDs
A comprehensive narrative review of adverse drug reactions and drug–drug interactions associated with over-the-counter NSAIDs (with emphasis on ibuprofen), detailing gastrointestinal, cardiovascular, and renal risks, interactions with common medications, and practical guidance f…
DOI: 10.2147/tcrm.s79135 -
Ibuprofen-associated acute kidney injury in dehydrated children with acute gastroenteritis
This study investigates the prevalence and risk factors of ibuprofen-associated acute kidney injury (AKI) in dehydrated children with acute gastroenteritis, finding a significant association between ibuprofen exposure and increased risk of AKI.
DOI: 10.1007/s00467-015-3105-7 -
The risk of cardiovascular thrombotic events with selective cyclooxygenase‐2 inhibitors
This study evaluates the cardiovascular thrombotic event risks associated with selective cyclooxygenase-2 inhibitors, specifically celecoxib and rofecoxib, in comparison to traditional NSAIDs, highlighting significant differences in adverse event rates between treatment groups.
DOI: 10.1002/art.10560 -
A randomised controlled trial of ibuprofen, paracetamol or a combination tablet of ibuprofen/paracetamol in community-derived people with knee pain
This study compares the efficacy and safety of single versus combination non-prescription oral analgesics in community-derived individuals aged 40 years and older with chronic knee pain, finding that ibuprofen/paracetamol combinations provide modest short-term benefits but may a…
DOI: 10.1136/ard.2011.154047